Axatilimab Shows Efficacy in Recurrent/Refractory GVHD
Highest overall response rate and least toxicity seen with lowest dose
Source: medpagetoday.com
Page 2 - Daniel Wolff News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Daniel Wolff. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Daniel Wolff Today - Breaking & Trending Today
Axatilimab Elicits Responses With Manageable Safety in Recurrent/Refractory cGVHD
Axatilimab induced rapid and durable responses with an acceptable toxicity profile at all doses analyzed with highest efficacy observed at the 0.3-mg/kg dose in patients with recurrent or refractory chronic graft-vs-host disease.
Source: onclive.com
Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease
WILMINGTON, Del. & WALTHAM, Mass.--(BUSINESS WIRE)--Dec 10, 2023--
Source: joplinglobe.com
Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease
- Trial met its primary endpoint across all dose cohorts with 74% of patients at the 0.3 mg/kg dose achieving a complete or partial response within the first six months of treatment - Data are...
Source: marketscreener.com
Coastal News Today | NY - She's on a Mission to Plumb the Secrets of New York's Disappearing Wetlands
It was 10 o’clock on an August morning, and the sun was already broiling.
Source: coastalnewstoday.com